Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
2 studies found for:    AP26113
Show Display Options
Rank Status Study
1 Recruiting A Phase 2, Multicenter, Randomized Study of AP26113
Conditions: Non-small Cell Lung Cancer;   Lung Cancer;   Advanced Malignancies;   Carcinoma
Intervention: Drug: AP26113
2 Active, not recruiting A Phase 1/2 Study of the Oral ALK/EGFR Inhibitor AP26113
Conditions: Advanced Malignancies;   Carcinoma, Non-Small-Cell Lung;   Anaplastic Large Cell Lymphoma;   Diffuse Large Cell Lymphoma;   Inflammatory Myofibroblastic Tumors
Intervention: Drug: AP26113

Indicates status has not been verified in more than two years